SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette SyndromeGlobeNewsWire · 4 days ago
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance ApplicationsGlobeNewsWire · Oct 19, 2026
SciSparc Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.69%Benzinga · Oct 15, 2026
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance TechnologiesGlobeNewsWire · Oct 15, 2026
SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum ArchitectureGlobeNewsWire · Oct 7, 2026
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine CombinationsGlobeNewsWire · Sep 23, 2026SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals.